Dual activation of autophagy and mTOR by TFE3 fusions promotes tumorigenesis in rearranged renal cell carcinoma
Carcinogenesis · 2025
DOI: 10.1093/carcin/bgaf080 ↗Kurz gefasst
Fachartikel in der Zeitschrift Carcinogenesis, 2025. Verfasst von Ruina Wu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Jinling Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing 210023, China. Hauptthemen laut MEDLINE: Basic Helix-Loop-Helix Leucine Zipper Transcription Factors, Carcinoma, Renal Cell, TOR Serine-Threonine Kinases, Kidney Neoplasms. Die Arbeit nennt 38 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Scientific Research Project of Jiangsu Health Commission, National Natural Science Foundation of Jiangsu Province.
Abstract (Originalsprache)
TFE3-rearranged renal cell carcinoma (TFE3-RCC), an aggressive kidney cancer predominantly affecting pediatric and young adult populations, is driven by Xp11.2 rearranged generating oncogenic TFE3 fusion proteins. Although these fusions define the disease, their mechanistic roles remain elusive. Here, lentiviral-mediated overexpression of PRCC-TFE3 or NONO-TFE3 in RCC models triggered nuclear rearranged fusion proteins and significantly accelerated tumor proliferation both in vitro and in vivo. Our integrated RNA sequencing (RNA-seq) and chromatin immunoprecipitation sequencing (ChIP-seq) analyses mechanistically revealed that TFE3 fusions directly bind to promoters of lysosome and mTOR signaling pathway genes, leading to transcriptional activation of this pathway. Moreover, the fusions aberrantly escaped canonical mTOR signaling pathway regulation and paradoxically hyperactivated phospho-mTOR signaling. Importantly, dual inhibition of the autophagy and mTOR pathways synergistically suppressed tumor growth, exceeding the efficacy of single-agent treatments. These data demonstrate that co-targeting these TFE3-regulated pathways represents a promising therapeutic strategy for this intractable malignancy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Jinling Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing 210023, China.
- Department of Pathology, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210002, China.
Förderung
- National Natural Science Foundation of China
- Scientific Research Project of Jiangsu Health Commission
- National Natural Science Foundation of Jiangsu Province
Zitieren
APA
Wu, R., Wang, X., Tian, M., Wei, X., Wang, X., Ye, S., Zhang, R., Xia, Q., Fang, R., & Rao, Q. (2025). Dual activation of autophagy and mTOR by TFE3 fusions promotes tumorigenesis in rearranged renal cell carcinoma. Carcinogenesis. https://doi.org/10.1093/carcin/bgaf080
Vancouver
Wu R, Wang X, Tian M, Wei X, Wang X, Ye S, et al. Dual activation of autophagy and mTOR by TFE3 fusions promotes tumorigenesis in rearranged renal cell carcinoma. Carcinogenesis. 2025. doi:10.1093/carcin/bgaf080
BibTeX
@article{Wu2025,
author = {Wu, Ruina and Wang, Xiaotong and Tian, Miaomiao and Wei, Xue and Wang, Xuan and Ye, Shengbing and Zhang, Rusong and Xia, Qiuyuan and Fang, Ru and Rao, Qiu},
title = {Dual activation of autophagy and mTOR by TFE3 fusions promotes tumorigenesis in rearranged renal cell carcinoma},
journal = {Carcinogenesis},
year = {2025},
doi = {10.1093/carcin/bgaf080}
}
EUVIMED